Patents by Inventor Steven A. Rosenberg

Steven A. Rosenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220372103
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: August 1, 2022
    Publication date: November 24, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20220362297
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Application
    Filed: February 17, 2022
    Publication date: November 17, 2022
    Inventors: Branden MORIARITY, Beau WEBBER, Modasir CHOUDHRY, Steven A. ROSENBERG, Douglas C. PALMER, Nicholas P. RESTIFO
  • Publication number: 20220368274
    Abstract: The present disclosure provides a device for window of a building or structure. The device comprises a panel having an area that is transparent for at least a portion of visible light and having opposite first and second major surfaces. The first major surface is a light receiving surface of the panel. The device further comprises at least one series of solar cells, each solar cell having a light receiving surface which faces the second major surface of the panel and is the directly or indirectly bonded to the panel at the second major surface in a manner such that light can be received by the light receiving surfaces of the solar cells without propagating through a gap between the panel and the light receiving surfaces of the solar cells. The at least one series of solar cells is positioned at and along an edge of the panel and between the edge and the area that is transparent for at least a portion of visible light.
    Type: Application
    Filed: October 1, 2020
    Publication date: November 17, 2022
    Applicant: CLEARVUE TECHNOLOGIES LTD
    Inventors: Jamie LYFORD, Victor ROSENBERG, Steven COONEN
  • Patent number: 11491187
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: November 8, 2022
    Assignees: Kite Pharma, Inc., The United States of America as Represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • Publication number: 20220352845
    Abstract: The present disclosure provides a device for generating electricity. The device comprises a panel having an area that is transparent for at least a portion of visible light and having a light receiving surface. The panel comprises at least one series of solar cells, each solar cell having opposite major surfaces having opposite electrical polarities, each solar cell overlapping another one of the solar cells and being electrically connected in series. The at least one series of solar cells is positioned along and in the proximity of an edge of the panel, along the area that is transparent for at least a portion of visible light and substantially parallel the light receiving surface of the panel.
    Type: Application
    Filed: October 1, 2020
    Publication date: November 3, 2022
    Applicant: CLEARVUE TECHNOLOGIES LTD
    Inventors: Jamie LYFORD, Victor ROSENBERG, Steven COONEN
  • Publication number: 20220332785
    Abstract: Disclosed are isolated or purified T cell receptors (TCRs) having antigenic specificity for human p53R175H or human p53Y220C. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 20, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Drew C. Deniger, Parisa Malekzadeh, Steven A. Rosenberg, Anna Pasetto
  • Patent number: 11466071
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: October 11, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rami Yoseph, Yong-Chen Lu, Gal Cafri, Steven A. Rosenberg
  • Publication number: 20220282208
    Abstract: Provided are methods of producing an isolated population of cells for adoptive cell therapy comprising use of at least one cell permeable Ca2+ dye. Further embodiments of the invention provide isolated populations of cells produced by the methods, related pharmaceutical compositions, and related methods of treating or preventing cancer in a patient.
    Type: Application
    Filed: September 18, 2020
    Publication date: September 8, 2022
    Applicant: THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Douglas C. Palmer, Anna Pasetto, Nicholas P. Restifo, Steven A. Rosenberg
  • Patent number: 11434272
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: September 6, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20220262483
    Abstract: A computer-implemented method including receiving, at a computing device, a first treatment plan designed to treat a cardiovascular health issue of a user. The first treatment plan comprises at least two exercise sessions that, based on the cardiovascular health issue, enable the user to perform an exercise at different exertion levels. While the user uses a treatment apparatus to perform the first treatment plan for the user, the computing device receives cardiovascular data from one or more sensors configured to measure the cardiovascular data associated with the user, and transmits the cardiovascular data. Wherein a machine learning model is used to generate a second treatment plan. The second treatment plan modifies at least one exertion level, and the modification is based on a standardized measure comprising perceived exertion, the cardiovascular data, and the cardiovascular health issue of the user. The method includes receiving the second treatment plan.
    Type: Application
    Filed: May 4, 2022
    Publication date: August 18, 2022
    Inventors: Joel Rosenberg, Jay L. Waddell, Steven Mason
  • Patent number: 11401503
    Abstract: An embodiment of the invention provides a method of promoting regression of cancer in a mammal comprising obtaining a tumor tissue sample from the mammal; culturing the tumor tissue sample in a first gas permeable container containing cell medium therein; obtaining tumor infiltrating lymphocytes (TIL) from the tumor tissue sample; expanding the number of TIL in a second gas permeable container containing cell medium therein using irradiated allogeneic feeder cells and/or irradiated autologous feeder cells; and administering the expanded number of TIL to the mammal. Methods of obtaining an expanded number of TIL from a mammal for adoptive cell immunotherapy are also provided.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: August 2, 2022
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Wilson Wolf Manufacturing Corporation
    Inventors: Steven A. Rosenberg, Mark E. Dudley, David Stroncek, Marianna Sabatino, Jianjian Jin, Robert Somerville, John R. Wilson
  • Patent number: 11390091
    Abstract: Embodiments of the present invention are directed to systems and methods for writing on electronic paper (“e-paper”) and display platforms implemented with e-paper. In one aspect, a system for writing information to electronic paper includes a writing module and an erasing unit connected to the writing module. The erasing unit is configured to erase information stored in the electronic paper. The system also includes a writing unit connected to the writing module and is configured to write information to the electronic paper. Information is written to the electronic paper by orienting the writing module so that the electronic paper passes the erasing unit prior to passing the writing unit.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: July 19, 2022
    Assignee: Hewlett-Packard Development Company, L.P.
    Inventors: Omer Gila, Napoleon J. Leoni, Steven Rosenberg, Henryk Birecki
  • Patent number: 11376318
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: July 5, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20220204584
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 30, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Gal Cafri, Paul F. Robbins, Steven A. Rosenberg
  • Publication number: 20220195008
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Application
    Filed: March 10, 2022
    Publication date: June 23, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Shiqui Zhu, Steven A. Feldman, Richard A. Morgan
  • Patent number: 11338032
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: May 24, 2022
    Assignee: The United States of Americans represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 11331385
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: May 17, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Publication number: 20220125843
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Application
    Filed: September 17, 2021
    Publication date: April 28, 2022
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, R. Scott McIvor, David Largaespada, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • Patent number: 11306131
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: April 19, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Shiqui Zhu, Steven A. Feldman, Richard A. Morgan
  • Patent number: 11306132
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: April 19, 2022
    Assignee: The United States of America, as represented by the Secretary Department of Health and Human Services
    Inventors: Rami Yoseph, Paul F. Robbins, Steven A. Rosenberg